HAE · Haemonetics Corp
$82.54
+2.63 (+3.29%)
At close · Jul 28
Market Cap
$3.75B
Shares
45.45M
Haemonetics Corp Earnings Call Transcripts
Every quarterly earnings call for Haemonetics Corp (HAE) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲14.4%
$261.46M
$19.88M
'23 Q1
22-08-10
▲24%
$297.49M
$33.20M
'23 Q2
22-11-07
▲17.5%
$305.30M
$32.94M
'23 Q3
23-02-07
▲14.9%
$304.42M
$29.38M
'23 Q4
23-05-11
▲19.1%
$311.33M
$41.04M
'24 Q1
23-08-08
▲7%
$318.18M
$24.91M
'24 Q2
23-11-02
▲10.1%
$336.25M
$31.24M
'24 Q3
24-02-08
▲12.8%
$343.29M
$20.37M
'24 Q4
24-05-09
▲8%
$336.17M
$38.37M
'25 Q1
24-08-08
▲8.6%
$345.51M
$33.83M
'25 Q2
24-11-07
▲3.7%
$348.54M
$37.49M
'25 Q3
25-02-06
▼3.7%
$330.60M
−$109.53M
'25 Q4
25-05-08
▼4.4%
$321.39M
$34.03M
'26 Q1
25-08-07
▼5.3%
$327.31M
$38.68M
'26 Q2
25-11-06
▼2.7%
$338.97M
$44.74M
'26 Q3
26-02-05
LATEST
▲4.8%
$346.35M
−$117.36M
'26 Q4
26-05-07
Earnings call
FY26 · Q4
2026-05-07
Haemonetics Corp Q4 FY2026 Earnings Call
Revenue
$346.35M*
▲ 4.8% YoY Gross margin
57.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY26 · Q3
2026-02-05
Haemonetics Corp Q3 FY2026 Earnings Call
Confident tone
Plasma franchise momentum
Interventional Technologies / vascular closure turnaround
Margin expansion and free cash flow
Revenue
$338.97M
▼ 2.7% YoY Diluted EPS
$0.95
▲ 28.4% YoY Gross margin
59.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2025-11-06
Haemonetics Corp Q2 FY2026 Earnings Call
Confident tone
Plasma business strength
FY26 guidance raise
Interventional Technologies / Vascular Closure turnaround
Revenue
$327.31M
▼ 5.3% YoY Diluted EPS
$0.81
▲ 22.7% YoY Gross margin
59.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2025-08-07
Haemonetics Corp Q1 FY2026 Earnings Call
Positive tone
Plasma / NexSys Performance
Blood Management Technologies / TEG
Guidance Reaffirmation and Long-Range Plan
Revenue
$321.39M
▼ 4.4% YoY Diluted EPS
$0.70
▼ 5.4% YoY Gross margin
59.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-05-08
Haemonetics Corp Q4 FY2025 Earnings Call
Positive tone
Plasma and CSL Transition
Hospital Business Growth
Capital Allocation and Share Buyback
Revenue
$330.60M*
▼ 3.7% YoY Gross margin
58.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-02-06
Haemonetics Corp Q3 FY2025 Earnings Call
Confident tone
Hospital segment growth
Whole blood divestiture and portfolio rationalization
Plasma business and CSL transition
Revenue
$348.54M
▲ 3.7% YoY Diluted EPS
$0.74
▲ 21.3% YoY Gross margin
55.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2024-11-07
Haemonetics Corp Q2 FY2025 Earnings Call
Positive tone
Plasma business and CSL transition
Guidance and outlook
Blood Management Technologies (TEG)
Revenue
$345.51M
▲ 8.6% YoY Diluted EPS
$0.66
▲ 37.5% YoY Gross margin
54.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2024-08-08
Haemonetics Corp Q1 FY2025 Earnings Call
Positive tone
Hospital / interventional technologies growth
International expansion (Japan and Europe)
Geopolitical and China headwinds
Revenue
$336.17M
▲ 8% YoY Diluted EPS
$0.74
▼ 7.5% YoY Gross margin
52.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-05-09
Haemonetics Corp Q4 FY2024 Earnings Call
Confident tone
FY2025 guidance and CSL headwind
Plasma business and Express Plus rollout
Acquisitions (OpSens and Attune)
Revenue
$343.29M*
▲ 12.8% YoY Gross margin
51.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-02-08
Haemonetics Corp Q3 FY2024 Earnings Call
Confident tone
Hospital segment momentum
Plasma franchise growth
OpSens acquisition and integration
Revenue
$336.25M
▲ 10.1% YoY Diluted EPS
$0.61
▼ 4.7% YoY Gross margin
52.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2023-11-02
Haemonetics Corp Q2 FY2024 Earnings Call
Revenue
$318.18M
▲ 7% YoY Diluted EPS
$0.48
▼ 25% YoY Gross margin
53.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2023-08-08
Haemonetics Corp Q1 FY2024 Earnings Call
Revenue
$311.33M
▲ 19.1% YoY Diluted EPS
$0.80
▲ 110.5% YoY Gross margin
53.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-05-11
Haemonetics Corp Q4 FY2023 Earnings Call
Revenue
$304.42M*
▲ 14.9% YoY Gross margin
51.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-02-07
Haemonetics Corp Q3 FY2023 Earnings Call
Revenue
$305.30M
▲ 17.5% YoY Diluted EPS
$0.64
▲ 42.2% YoY Gross margin
52.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2022-11-07
Haemonetics Corp Q2 FY2023 Earnings Call
Revenue
$297.49M
▲ 24% YoY Diluted EPS
$0.64
▲ 120.7% YoY Gross margin
53.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2022-08-10
Haemonetics Corp Q1 FY2023 Earnings Call
Revenue
$261.46M
▲ 14.4% YoY Diluted EPS
$0.38
Gross margin
54.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-05-10
Haemonetics Corp Q4 FY2022 Earnings Call
Revenue
$265.00M*
▲ 17.8% YoY Gross margin
51.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-02-08
Haemonetics Corp Q3 FY2022 Earnings Call
Revenue
$259.77M
▲ 8.1% YoY Diluted EPS
$0.45
▼ 27.4% YoY Gross margin
53.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2021-11-09
Haemonetics Corp Q2 FY2022 Earnings Call
Revenue
$239.90M
▲ 14.5% YoY Diluted EPS
$0.29
▼ 69.1% YoY Gross margin
51.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2021-08-11
Haemonetics Corp Q1 FY2022 Earnings Call
Revenue
$228.53M
▲ 16.8% YoY Diluted EPS
$-0.09
▼ 142.9% YoY Gross margin
47.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-05-13
Haemonetics Corp Q4 FY2021 Earnings Call
Revenue
$225.03M
▼ 5.6% YoY Diluted EPS
$-0.22
▼ 164.7% YoY Gross margin
36.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-02-02
Haemonetics Corp Q3 FY2021 Earnings Call
Revenue
$240.37M
▼ 7.2% YoY Diluted EPS
$0.62
▲ 6.9% YoY Gross margin
50.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2020-11-04
Haemonetics Corp Q2 FY2021 Earnings Call
Revenue
$209.49M
▼ 17.1% YoY Diluted EPS
$0.94
▲ 30.6% YoY Gross margin
50.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2020-06-30
Haemonetics Corp Q1 FY2021 Earnings Call
Revenue
$195.58M
▼ 18% YoY Diluted EPS
$0.21
Gross margin
46.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-05-05
Haemonetics Corp Q4 FY2020 Earnings Call
Revenue
$238.49M
▼ 4.3% YoY Diluted EPS
$0.34
▼ 15% YoY Gross margin
47.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-02-04
Haemonetics Corp Q3 FY2020 Earnings Call
Revenue
$258.97M
▲ 4.7% YoY Diluted EPS
$0.58
▲ 65.7% YoY Gross margin
49.4%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Showing 1–26 of 26 earnings calls
Key facts
CIK
313143
CUSIP
405024100
13F (30d)
66 filings
66 filers
Visit website
Investor relations